- Home
- PMO vs ABEO Comparison
PMO vs ABEO Comparison
Compare PMO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMO | ABEO |
|---|---|---|
| Founded | 1993 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 320.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PMO | ABEO |
|---|---|---|
| Price | $10.74 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 64.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.71 | $4.00 |
| 52 Week High | $10.87 | $7.54 |
Technical Indicators
Market Signals| Indicator | PMO | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 62.80 |
| Support Level | $10.27 | $5.19 |
| Resistance Level | $10.78 | N/A |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 68.91 | 66.69 |
Price Performance
Historical ComparisonAbout PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, leases, local, Housing, education, and Others.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.